Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial…
MENLO PARK, Calif., Dec. 3, 2024 /PRNewswire/ -- Avails Medical, Inc., a leader in rapid, automated, and fully electrical antibiotic susceptibility…
- STAR-1 topline results expected in March 2025 -- Over 30 million acne patients seek treatment in the U.S. each…
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026,…
BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare GlobalWINNIPEG, Manitoba, Nov. 27, 2024…
SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic…
NORTHAMPTON, MA / ACCESSWIRE / November 20, 2024 / Antimicrobial resistance (AMR) happens when bacteria no longer respond to antibiotics,…
Additions of ProgenaMatrix® and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolioPOMPANO BEACH, Fla., Nov.…
Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with cash…
Proprietary 3D-Printing Resin Used by Glidewell Has Been Shown In Vitro to Produce Dentures With Antibacterial and Antifungal Effects NEWPORT…